EMD Serono to announce long-term data in numerous cancers at ESMO 2020

EMD Serono to announce long-term data in numerous cancers at ESMO 2020

by Pranali Mehta

EMD Serono Inc., the biopharmaceutical business of Germany-based Merck KGaA in the United States and Canada, has reportedly announced that it will present over 30 abstracts related to the company’s clinical studies in oncology at ESMO (the European Society for Medical Oncology) Virtual Congress 2020, which will be held between Sept. 19 -21.

The abstracts span EMD’s oncology programs across numerous innovative mechanisms and modalities that have the potential to advance treatment across a range of tumor types including lung, biliary tract, and urothelial cancers.

Sources cite that EMD will present new outcomes from Phase III JAVELIN Bladder 100 clinical trial of BAVENCIO® that evaluated efficacy across patient-reported outcomes, subgroups, and exploratory biomarkers in advanced urothelial cancer. Examines of brain metastases, overall efficacy outcomes and HRQoL of tepotinib† from the biggest ongoing clinical trial in NSCLC harboring METex14 skipping will also be demonstrated at a virtual meet.

Moreover, the company will present complete long period follow-up outcomes regarding new bifunctional fusion protein aiming TGF-β/PD-L1, bintrafusp alfa‡, in BTC and NSCLC, which showed sustained durability of response.

Speaking on which, Luciano Rossetti, Global Head of R&D for EMD Serono said that the company’s oncology department aims to develop innovative treatments with transformative results. The outcomes being presented in urothelial cancer patients demonstrate this approach in action, where the company is recording promising results for a novel first-line maintenance treatment option with BAVENCIO® in cancer patients, he stated.

Mr. Rossetti added that prolonged period follow-up data in lung cancer from two of the company’s developed mechanisms i.e., oral MET inhibitor ‘tepotinib’ and bifunctional fusion protein immunotherapy aiming TGF TGF-β/PD-L1, bintrafusp alfa, is showing the sustained effect on the leading cause of cancer mortality.

For the record, EMD is engaged in research, discovery, and development of medicines for patients with difficult to treat diseases such as cancer.

Source Credit - https://www.prnewswire.com/news-releases/emd-serono-advances-oncology-portfolio-and-pipeline-with-new-and-long-term-data-in-multiple-cancers-at-esmo-2020-301129750.html

Pranali Mehta

A chemical engineer by qualification, Pranali Mehta dutifully walked down the slated path and worked in a chemical firm for a year. Her passion for writing however, pushed her into experimenting with the same as a career. With over three years of experience in content writ Read more...